Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights [Yahoo! Finance]
Invivyd, Inc. (IVVD)
Company Research
Source: Yahoo! Finance
PEMGARDA product availability in the U.S. anticipated imminently PEMGARDA is the first authorized mAb from Invivyd's INVYMAB™ platform approach designed to address the challenge of rapid viral evolution Leveraged INVYMAB platform approach to design VYD2311, the company's next anticipated SARS-CoV-2 candidate Cash and cash equivalents of $200.6 million as of December 31, 2023 In February 2024, the Company sold shares totaling $40.5 million in gross proceeds under its At-the-Market facility further strengthening its balance sheet ahead of PEMGARDA launch WALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced financial results for the full year ended December 31, 2023 and recent business highlights. “We made remarkable progress throughout 2023 and in recent months. Roughly one year ago we were initiating the Phase 1 clinical tri
Show less
Read more
Impact Snapshot
Event Time:
IVVD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IVVD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IVVD alerts
High impacting Invivyd, Inc. news events
Weekly update
A roundup of the hottest topics
IVVD
News
- Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA FeedbackGlobeNewswire
- Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights [Yahoo! Finance]Yahoo! Finance
- Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business HighlightsGlobeNewswire
- Invivyd cuts 14 positions, expects to end 2024 with at least $75M in cash [Seeking Alpha]Seeking Alpha
- Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash PositionGlobeNewswire
IVVD
Earnings
- 11/9/23 - Beat
IVVD
Sec Filings
- 5/7/24 - Form 8-K
- 4/22/24 - Form EFFECT
- 4/18/24 - Form ARS
- IVVD's page on the SEC website